Premium
Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: one year follow‐up
Author(s) -
KORT F,
BOURAOUI R,
CHEBIL A,
CHAKER N,
CHAABOUNI A,
MGHAIETH F,
EL MATRI L
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.435.x
Subject(s) - angioid streaks , medicine , choroidal neovascularization , ophthalmology , bevacizumab , visual acuity , fluorescein angiography , retinal , surgery , chemotherapy
Purpose To evaluate the efficay and safety of intravitreal bevacizumab at one year follow‐up, for the treatment of choroidal neovascularization (CNV) associated with angioid streaks. Methods Consecutive series of 16 eyes with subfoveal or juxtafoveal CNV secondary to angioid streaks, treated with intravitreal bevacizumab (1.25 mg in 0.05 ml) between January 2007 and March 200, were reviewed retrospectively. Ophthalmic examination including best corrected visual acuity (BCVA), optical coherence tomography (OCT) and fluorescein angiography, was performed before and after treatment. Retreatment was given every six weeks in case of persisting symptoms or CNV activity on OCT. The main outcome measures were changes in BCVA and central retinal thickness on OCT at the 1‐year follow‐up. Results The mean number of injections was 4.6 at one year. Ten eyes (62.5%) received more than five injections. The mean BCVA at baseline was 20/81 (range 20/400 to 20/32) and improved to 20/40 (range 20/100 to 20/20) at one year (p=0.055). The BCVA improved by three or more lines in ten eyes (62.5%) and remained within two lines of baseline in six eyes (37.5%). Mean central retinal thickness was 404.2µm at baseline (range 160 to 602 µm) and decreased to 293.3µm (range 150 to 490µm) at one year (p=0.006). No ocular or systemic complications were noted. Conclusion The one‐year outcomes suggest intravitreal bevacizumab to be a promising treatment for CNV associated with angioid streaks, resulting in both functional and anatomical improvements. Repeated injections are needed to maintain these results.Further controlled, prospective and long term evaluations of this treatment are warranted.